Kraig Biocraft Laboratories Announces That Henry Wendt Has Joined Its Business Advisory Board
November 09 2010 - 6:05AM
Marketwired
Kraig Biocraft Laboratories, Inc.
(PINKSHEETS: KBLB) announced today that Henry Wendt, the renowned
former head of SmithKline Beecham, has joined the Company's Board
of Advisors.
Wendt is the former CEO and Chairman of SmithKline Beecham, one
of the world's largest and most successful corporations. He has an
unparalleled track record for fostering and managing corporate
growth through mergers and acquisitions, as well as through organic
growth and global marketing. In fact, he is generally recognized as
the principal architect of the successful merger which created
SmithKline Beecham.
"Henry Wendt is one of the top CEOs on the planet, with a proven
Fortune 500 track record," said Kraig Biocraft Laboratories CEO,
Kim K. Thompson. "In addition to his groundbreaking leadership at
SmithKline Beecham, he literally wrote the book on successful
strategies for corporate growth in the global marketplace. Mr.
Wendt's book Global Embrace: Corporate Challenges in a
Transnational World is, in my opinion, a 'must read' for corporate
executives. We are very fortunate and excited to have him on our
team. I know that, as a member of our advisory board, his insight
and advice will be invaluable, as we grow and commercialize our
revolutionary technologies."
Kraig Biocraft Laboratories is a fully reporting biotechnology
company, which recently achieved a series of scientific
breakthroughs with implications for the global textile
industry.
To learn more about Kraig Biocraft Laboratories and its recent
commercial and scientific breakthroughs please visit
www.KraigLabs.com. The website hosts several short videos
describing the Company's recent commercial and technological
breakthroughs and outlines the commercial potential that has
garnered attention of many scientific and trade journals.
Statements in this press release about the company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "hopes," "develops," "researching," "research,"
"potential," "implications," "could" or other words or phrases of
similar import. Similarly, statements in this release that describe
the Company's business strategy, outlook, objectives, plans,
intentions or goals should all be considered forward-looking
statements. All such forward-looking statements are subject to
certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements.
Management cautions that its ability to further its research, and
create commercially-viable products may be affected by the
competitive environment, the Company's financial condition and its
ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing
operations.
Contact: Ben Hansel (720) 288-8495 Email Contact
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2024 to Jun 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Jun 2023 to Jun 2024